RightEye strikes deal with MIT to research Ocular

BETHESDA, Md., April 25, 2022 (GLOBE NEWSWIRE) — RightEye, the world leader in eye-tracking biomarkers, has signed a research collaboration agreement with the Massachusetts Institute of Technology (MIT) to study a “signature” oculomotor Lyme disease. This approach promises to be the most accurate indicator of Lyme disease in the world. Current “gold standard” diagnostic tests, including the enzyme-linked immunosorbent assay (ELISA) and the Western Blot Test, have widely accepted shortcomings.

MIT researchers will be responsible for recruiting participants and conducting testing with control and experimental groups using the RightEye vision system. The studies will look at people with acute Lyme and chronic symptoms after Lyme infection. The study aims to determine if ocular motor function can be used to generate a highly accurate, non-invasive and sensitive biomarker for Lyme disease.

According to the CDC, reported cases of Lyme disease have nearly tripled over the past two decades. With tick populations increasing due to climate change and environmental factors, experts fear their numbers will continue to rise. To compound this problem, diagnosing Lyme disease is not always an easy task. Not all patients develop the signature “bulls-eye rash” associated with the disease. On the contrary, patients often present with ambiguous symptoms such as fever, fatigue and joint pain. In more progressive cases of the disease, patients may experience neuropathy, mental fog, arthritis, and heart palpitations. Lyme disease is often called “the great imitator” for its ability to mimic other conditions, baffling doctors and suffering patients alike.

Commenting on the study, Scientific Director and Co-Founder of RightEye, Dr. Melissa Hunfalvay, said, “The widely accepted shortcomings of ELISA and Western Blot testing greatly increase the importance of this study. These tests are based on the presence of antibodies directed against the bacteria. that causes Lyme disease, rather than detecting the disease itself. Although these blood tests are useful tools for diagnosing Lyme disease, they rely on the patient’s immune response to generate a positive test result with varying levels of success. During the early stages of the disease, antibodies may be too few for detection, leading to false negatives. A more objective and reliable form of detection is needed if we are to accurately diagnose this disease in its early stages.

Dr. Michal Caspi Tal, Instructor and Team Leader at Stanford University’s Institute of Stem Cell Biology and Regenerative Medicine and Visiting Scholar in MIT’s Department of Bioengineering Noted, “More than 10% of people with Lyme disease continue to suffer from a chronic illness. It is not known why some regain their health while others do not. We hope that this research will provide answers to those who develop chronic symptoms after Lyme disease. This could lead to interventions that can reduce or even alleviate chronic symptoms after Lyme disease.”

About RightEye

RightEye is an eye movement behavioral biomarker company that uses advanced eye tracking technology to revolutionize eye care and provide essential medical research. RightEye technology assesses patients for binocular vision, visual impairment, reading impairment, and ocular motor performance issues following an evidence-based, measurement-driven methodology. Using an advanced cloud-based platform, the RightEye Vision System provides data-rich reporting and analytics that provide an objective and measurable way to visualize the quality of a person’s eye movements and monitor the success of various treatments. RightEye’s customers include recognized eye care providers, professional and amateur sports teams, hospital systems, rehabilitation centers and the US military.

For more information, visit www.RightEye.com and follow us on Facebook, Twitter, Instagram and LinkedIn.

Media Contact:

Amanda Sims
Marketing director
[email protected]

Related images

Image 1: MIT PR Lyme disease tick

This content was posted through the press release distribution service on Newswire.com.

Comments are closed.